Immix Biopharma, Inc. financial data

Symbol
IMMX on Nasdaq
Location
11400 West Olympic Blvd., Suite 200, Los Angeles, CA
Fiscal year end
December 31
Latest financial report
10-Q - Q2 2025 - Aug 8, 2025

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 208 % -67.2%
Debt-to-equity 35 % +106%
Return On Equity -205 % -136%
Return On Assets -111 % -53.5%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 28.8M shares +5.04%
Common Stock, Shares, Outstanding 28.4M shares +3.56%
Entity Public Float 32.4M USD +16%
Common Stock, Value, Issued 2.85K USD +3.45%
Weighted Average Number of Shares Outstanding, Basic 30M shares +4.16%
Weighted Average Number of Shares Outstanding, Diluted 30M shares +4.16%

Income Statement

Label TTM Value / Value Unit Change %
Research and Development Expense 11.8M USD +10.2%
General and Administrative Expense 12M USD +26.3%
Operating Income (Loss) -23.8M USD -17.8%
Nonoperating Income (Expense) 697K USD -29.6%
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest -23.1M USD -20.2%
Income Tax Expense (Benefit) 40.7K USD +19.6%
Net Income (Loss) Attributable to Parent -23.1M USD -21.6%
Earnings Per Share, Basic 0 USD/shares +9.52%
Earnings Per Share, Diluted 0 USD/shares +9.52%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 11.6M USD -51.5%
Other Assets, Current 138K USD +30.2%
Assets, Current 12.3M USD -54.9%
Property, Plant and Equipment, Net 2.23M USD +391%
Operating Lease, Right-of-Use Asset 947K USD -8.11%
Other Assets, Noncurrent 20.4K USD 0%
Assets 15.6M USD -45.8%
Accounts Payable, Current 6.61M USD +182%
Employee-related Liabilities, Current 703K USD +312%
Liabilities, Current 10M USD +157%
Operating Lease, Liability, Noncurrent 972K USD -6.76%
Liabilities 11M USD +122%
Accumulated Other Comprehensive Income (Loss), Net of Tax 65K USD -44.4%
Retained Earnings (Accumulated Deficit) -86.2M USD -36.7%
Stockholders' Equity Attributable to Parent 13.3M USD -19.2%
Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest 4.65M USD -80.5%
Liabilities and Equity 15.6M USD -45.8%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -1.69M USD +56%
Net Cash Provided by (Used in) Financing Activities 15.9M USD +13312%
Net Cash Provided by (Used in) Investing Activities -67.7K USD +77.6%
Common Stock, Shares Authorized 200M shares 0%
Common Stock, Shares, Issued 28.5M shares +3.55%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect -1.76M USD -115%
Deferred Tax Assets, Valuation Allowance 15.8M USD +107%
Operating Lease, Liability 1.04M USD -4.43%
Depreciation 38.2K USD +1168%
Payments to Acquire Property, Plant, and Equipment 67.7K USD -77.6%
Comprehensive Income (Loss), Net of Tax, Attributable to Parent -21.7M USD -41.4%
Lessee, Operating Lease, Liability, to be Paid 1.46M USD -9.06%
Property, Plant and Equipment, Gross 64.5K USD 0%
Operating Lease, Liability, Current 70.5K USD +45.7%
Lessee, Operating Lease, Liability, to be Paid, Year Two 158K USD +3.5%
Lessee, Operating Lease, Liability, to be Paid, Year One 153K USD +3.5%
Operating Lease, Weighted Average Discount Rate, Percent 0.08 pure 0%
Lessee, Operating Lease, Liability, Undiscounted Excess Amount 416K USD -18.9%
Lessee, Operating Lease, Liability, to be Paid, Year Three 164K USD +3.5%
Deferred Tax Assets, Operating Loss Carryforwards 6.71M USD +64.4%
Preferred Stock, Shares Issued 0 shares
Preferred Stock, Shares Authorized 10M shares 0%
Lessee, Operating Lease, Liability, to be Paid, Year Four 164K USD
Additional Paid in Capital 90.9M USD +4.53%
Preferred Stock, Shares Outstanding 0 shares
Share-based Payment Arrangement, Expense 590K USD +167%
Preferred Stock, Par or Stated Value Per Share 0 USD/shares 0%